Centro de Investigación Biomédica en Red de Cáncer-ko ikertzaileekin lankidetzan egindako argitalpenak (31)

2024

  1. KRAS-mutant non-small cell lung cancer (NSCLC) therapy based on tepotinib and omeprazole combination

    Cell Communication and Signaling, Vol. 22, Núm. 1

  2. Soluble galectin-3 as a microenvironment-relevant immunoregulator with prognostic and predictive value in lung adenocarcinoma

    Molecular Oncology, Vol. 18, Núm. 1, pp. 190-215

2023

  1. A Sonic Hedgehog Pathway Score to Predict the Outcome of Resected Non-Small Cell Lung Cancer Patients

    Annals of Surgical Oncology, Vol. 30, Núm. 2, pp. 1225-1235

  2. ASO Visual Abstract: A Sonic Hedgehog Pathway Score to Predict the Outcome of Resected Non-small Cell Lung Cancer Patients

    Annals of surgical oncology, Vol. 30, Núm. 2, pp. 1238-1239

  3. Addressing lung cancer screening eligibility in Spain using 2013 and 2021 US Preventive Service Task Force criteria: cross-sectional study

    ERJ Open Research, Vol. 9, Núm. 6

  4. Circulating Immune Proteins: Improving the Diagnosis and Clinical Outcome in Advanced Non-Small Cell Lung Cancer

    International Journal of Molecular Sciences, Vol. 24, Núm. 24

  5. Clinical and technical insights of tumour mutational burden in non-small cell lung cancer

    Critical Reviews in Oncology/Hematology, Vol. 182

2022

  1. Capillary and cutaneous hypopigmentation secondary to pazopanib

    Medicina Clinica

  2. Determination of essential biomarkers in lung cancer: a real-world data study in Spain with demographic, clinical, epidemiological and pathological characteristics

    BMC Cancer, Vol. 22, Núm. 1

  3. Relation of Malnutrition and Nosocomical Infections in Cancer Patients in Hospital: An Observational Study

    Journal of Nutrition and Metabolism, Vol. 2022

2021

  1. 3D printing novel in vitro cancer cell culture model systems for lung cancer stem cell study

    Materials Science and Engineering C, Vol. 122

  2. Exosomal microRNAs in non-small cell lung cancer

    Translational Cancer Research, Vol. 10, Núm. 6, pp. 3128-3139

  3. LungBEAM: A prospective multicenter study to monitor stage IV NSCLC patients with EGFR mutations using BEAMing technology

    Cancer Medicine, Vol. 10, Núm. 17, pp. 5878-5888

  4. NGS-based liquid biopsy profiling identifies mechanisms of resistance to ALK inhibitors: a step toward personalized NSCLC treatment

    Molecular Oncology, Vol. 15, Núm. 9, pp. 2363-2376

  5. dPCR application in liquid biopsies: divide and conquer

    Expert Review of Molecular Diagnostics, Vol. 21, Núm. 1, pp. 3-15

2020

  1. A profile on cobas® EGFR Mutation Test v2 as companion diagnostic for first-line treatment of patients with non-small cell lung cancer

    Expert Review of Molecular Diagnostics, Vol. 20, Núm. 6, pp. 575-582

  2. CD5 and CD6 as immunoregulatory biomarkers in non-small cell lung cancer

    Translational Lung Cancer Research, Vol. 9, Núm. 4, pp. 1074-1083

  3. Development of a multicriteria decision analysis framework for evaluating and positioning oncologic treatments in clinical practice

    Journal of Oncology Practice

  4. Potential treatment strategy for the rare osimertinib resistant mutation EGFR L718Q

    Journal of Thoracic Disease, Vol. 12, Núm. 5, pp. 2771-2780

  5. Safe neoadjuvant trastuzumab-based treatment in HER2 + inflammatory early breast cancer in a glucose 6-phosphate dehydrogenase-deficient postmenopausal woman: A case report and review of the literature

    Journal of Oncology Pharmacy Practice, Vol. 26, Núm. 2, pp. 492-495